下一个

自动播放

Upfront Immunotherapy for Metastatic Kidney Cancer

0 意见 • 06/26/23
分享
嵌入
administrator
administrator
订户
0

Panelists Robert A. Figlin, MD, and Eric Jonasch, MD, provide insight on the implications of frontline trials for immunotherapy and cabozantinib use, and the rationale for combination trials for metastatic kidney cancer.

显示更多
0 注释 sort 排序方式
脸书评论

下一个

自动播放